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Abstract

Antimicrobial photodynamic inactivation (aPDI) uses photosensitizers (PSs) and harmless visible light to
generate reactive oxygen species (ROS) and kill microbes. Multidrug efflux systems can moderate the
phototoxic effects of PSs by expelling the compounds from cells. We hypothesized that increasing intracellular
concentrations of PSs by inhibiting efflux with a covalently attached efflux pump inhibitor (EPI) would
enhance bacterial cell phototoxicity and reduce exposure of neighboring host cells to damaging ROS. In this
study, we tested the hypothesis by linking NorA EPIs to methylene blue (MB) and examining the
photoantimicrobial activity of the EPI-MB hybrids against the human pathogen methicillin-resistant
Staphylococcus aureus (MRSA). Photochemical/photophysical and in vitro microbiological evaluation of 16
hybrids carrying four different NorA EPIs attached to MB via four linker types identified INF55-(Ac)en-MB
12 as a lead. Compound 12 showed increased uptake into S. aureus cells and enhanced aPDI activity and
wound healing effects (relative to MB) in a murine model of an abrasion wound infected by MRSA. The study
supports a new approach for treating localized multidrug-resistant MRSA infections and paves the way for
wider exploration of the EPI-PS hybrid strategy in aPDI.
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ABSTRACT
Antimicrobial photodynamic inactivation (aPDI) uses photosensitizers (PSs) and harmless
visible light to generate reactive oxygen species (ROS) and kill microbes. Multidrug efflux
systems can moderate the phototoxic effects of PSs by expelling the compounds from cells.
We hypothesized that increasing intracellular concentrations of PSs by inhibiting efflux with
a covalently attached efflux pump inhibitor (EPI) would enhance bacterial cell phototoxicity
and reduce exposure of neighbouring host cells to damaging ROS. In this study, we tested the
hypothesis by linking NorA EPIs to methylene blue (MB) and examining the
photoantimicrobial activity of the EPI-MB hybrids against the human pathogen methicillinresistant Staphylococcus aureus (MRSA). Photochemical/photophysical and in vitro
microbiological evaluation of sixteen hybrids carrying four different NorA EPIs attached to
MB via four linker-types identified INF55-(Ac)en-MB 12 as a lead. Compound 12 showed
increased uptake into S. aureus cells and enhanced aPDI activity and wound healing effects
(relative to MB) in a murine model of an abrasion wound infected by MRSA. The study
supports a new approach for treating localized multidrug-resistant MRSA infections and
paves the way for wider exploration of the EPI-PS hybrid strategy in aPDI.

Keywords: antimicrobial photodynamic inactivation; photosensitizer-efflux pump inhibitor
hybrid; methicilllin resistant Staphylococcus aureus; reactive oxygen species;
bioluminescence wound infection model
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Methicillin-resistant Staphylococcus aureus (MRSA) infections have emerged as a
major medical threat over the past two decades.1 Despite a downward mortality trend in
Europe, MRSA remains a major cause of serious skin and soft-tissue infections,2-4
community-acquired pneumonia and catheter-related bloodstream infections, and is
responsible for the majority of recurrent infections in immunocompromised patients.5 Several
classes of antibiotics have been used to treat MRSA infections over the years, including the
topically applied mupirocin, later generation β-lactams, broad spectrum tetracyclines,
linezolid, the lipopeptide daptomycin, the glycopeptide vancomycin and the recently
approved lipoglycopeptides telavancin, oritavancin and dalbavancin.6 Some of these
antibiotics have, or will likely become, ineffective against MRSA due to the development of
resistance, thus ensuring an ongoing need for new antibiotics and treatment strategies
targeting this significant human pathogen.7
Multidrug resistance often arises due to transmembrane efflux systems, which serve to
pump noxious compounds from microbial cells.8 Efflux systems in Gram-positive cocci (e.g.
MRSA) tend to exhibit broad and overlapping substrate specificities, with many compounds
(e.g. antibiotics, monovalent and divalent biocides, intercalating dyes, quaternary ammonium
salts, diamidines, biguanidines and plant secondary metabolites) acting as efflux pump
substrates.9 Efflux-mediated resistance in Staphylococci has been attributed to pumps from
the chromosomally encoded Major Facilitator Superfamily (MFS: NorA, NorB, NorC,
MdeA),10 the Multi-Antimicrobial Extrusion protein family (MATE: mepA),10 Small
Multidrug Resistance proteins (SMR: SepA)11 and the plasmid encoded systems QacA, QacB
and Tet(K).12-14 The NorA pump has been extensively studied in S. aureus, including as a
discovery target for small molecule efflux pump inhibitors (EPIs).15
Photodynamic therapy (PDT) is a light-based technology that harnesses the combined
power of visible or near-visible light and photosensitizers (PSs) to kill cells. PSs are typically
3

non-toxic, highly conjugated aromatic molecules that exert photodynamic activity through
reactions with molecular oxygen.16 Illumination with light of a suitable wavelength and
reaction of the excited-state PSs with O2 generates reactive oxygen species (ROS) (e.g.
singlet oxygen 1O2 and hydroxyl radicals •OH) that cause non-specific cell damage and
death. While PDT has been widely explored in the treatment of cancer17 and age-related
macular degeneration,18 antimicrobial photodynamic inactivation (aPDI) has only more
recently emerged as a powerful sterilization technique and promising treatment for localized
bacterial infections.19 The phenothiazinium PSs methylene blue (MB) and toluidine blue O
(TBO), for example, are used for photodynamic sterilization of blood products and aPDI oral
cavity disinfection.20-23
Efflux pumps have been shown to moderate bacterial cell killing during aPDI with
MB, apparently by lowering intracellular MB concentrations and associated (intracellular)
ROS.24 This suggested that combination approaches, where MB is co-administered with a
small molecule efflux pump inhibitor (EPI), should potentiate aPDI by increasing
intracellular MB and associated ROS, thus triggering more damaging intracellular
photodynamic reactions. Additionally, better localization of PSs to the bacterial intracellular
space would reduce the damaging effects of the ROS generated in solution on neighboring
host cells at infection sites, which could aid wound healing. Studies by Tegos et al.
demonstrated that combinations of NorA EPIs and MB (a well-characterised NorA substrate)
show enhanced PDI of S. aureus relative to MB alone.25
We previously reported an efflux pump inhibitor-antibacterial hybrid strategy for
addressing NorA efflux-mediated resistance in S. aureus. The prototype hybrid (SS14)
containing berberine, a weak antibacterial natural product and NorA substrate,26, 27 covalently
linked to the synthetic NorA EPI 5-nitro-2-phenylindole (INF55), showed potent antibacterial
activity, rapidly accumulated in S. aureus cells and was more effective than co-administered
4

berberine/INF55 combinations in a Caenorhabditis elegans model of enterococcal
infection.28 Analogues of SS14 showed remarkably similar effects indicating that significant
structural changes could be introduced into the hybrids without diminishing antibacterial
action.29, 30
Phenothiazinium photosensitizers (e.g. MB) are amphipathic, planar, polycyclic
aromatic cations and physicochemically similar to the quaternary ammonium aromatic
alkaloid berberine. The structural and physicochemical similarities between berberine and
MB, combined with the known susceptibility of both compounds to NorA-mediated efflux,27
suggested that a NorA EPI-MB hybrid strategy might be successfully applied in aPDI of S.
aureus. We hypothesized that the hydrophobic/cationic EPI-MB hybrids would, in a similar
fashion to MB, spontaneously enter S. aureus cells due to the negative membrane potential.31
Unlike MB, however, the hybrids would resist efflux due to the attached NorA EPI. The
higher resulting intracellular hybrid concentrations would amplify intracellular ROS
(following illumination) leading to enhanced lethality compared to MB, whose photodynamic
reactions are restricted by efflux mostly to the cell exterior (Figure 1, Top). Importantly, EPIMB hybrids would be more attractive for clinical development than PS/EPI inhibitor
combinations due to the simpler scientific (i.e. active pharmaceutical ingredient/formulation
optimization, administration and delivery) and regulatory approval pathway for single agent
therapeutics.
This study aimed to test the hypothesis by: (1) identifying a lead EPI-MB hybrid that
shows increased uptake into S. aureus cells and enhanced in vitro PDI of S. aureus relative to
MB alone, and (2) demonstrating that the selected lead shows enhanced PDI activity (relative
to MB) in a murine MRSA localized wound infection model. A focussed 16-member EPIMB hybrid library was rationally designed and synthesised and its members systematically
screened using photochemical, photophysical and in vitro microbiological assays with S.
5

aureus. Compound INF55(Ac)en-MB 12 emerged as the lead hybrid and was subsequently
examined alongside MB for in vivo aPDI effects against MRSA. Experiments probing the
mechanism of enhanced PDI activity with INF55(Ac)en-MB 12 were also explored.
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Figure 1. Proposed mechanism for enhanced PDI of S. aureus cells by EPI-MB hybrids
relative to MB (Top). Structures of hybrids 1-16 (Bottom).
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RESULTS AND DISCUSSSION
Library design and synthesis
At the outset of the study it was not known if linking NorA EPIs to MB would
adversely impact EPI activities or the photochemical properties of MB. A medicinal
chemistry approach was therefore adopted, where a focused library of 16 hybrids was
synthesized with members containing four known NorA EPIs attached to MB via four
different linker types. The structural variants were designed to systematically scan EPI-MB
chemical space and increase the likelihood of identifying a lead hybrid for in vivo studies.
When designing EPI-MBs, we rationalized that only minimal structural modifications
should be introduced at the phenothiazinium moiety in order to maintain the photosensitizer
properties of MB. Such changes were considered less likely to impact ROS generation via the
Type I (radical formation) and Type II (singlet oxygen formation) photochemical reactions of
MB.32 In the first compound series (1,3,5,7,9,11,13,15), the N-(CH3)2 group at the C-7
position of MB was replaced with a piperazine-based linker to direct EPIs away from the MB
moiety. The second series (2,4,6,8,10,12,14,16) employed more flexible N,N’dimethylethylenediamine-based linkers. Four S. aureus NorA efflux pump inhibitors
(reserpine,33 pterostilbene,34 INF5535 and INF27135) were appended to the linkers using both
N-alkyl and N-acyl attachments as a way of systematically varying hybrid polarity and
basicity. The structures of 1-16 are shown in Figure 1 (Bottom) and full details of their
syntheses are provided in the Supporting Information, Section 1 ̶ Chemistry.

UV/Visible Spectroscopy
The absorption properties of the MB chromophore in hybrids 1-16 were probed using
UV/visible spectroscopy. MB shows strong absorption bands between 550-700 nm,
displaying an intense maximum at λmax1 = 668 nm and a shoulder at λmax2 = 609 nm.36 Large
8

differences in wavelength and/or extinction coefficients at λmax1 and λmax2 for hybrids
compared to MB would indicate that the structural modifications had altered the absorption
properties of the chromophore. Hybrids exhibiting such changes were considered less likely
to maintain the photosensitizer and aPDI properties of MB. UV/Visible spectra (Supporting
Information, Supplementary Figure 5) and wavelength/extinction coefficient data (Supporting
Information, Supplementary Figure 6) revealed that the λmax1 and λmax2 absorption bands
varied little among MB and the hybrids, confirming that attachment of EPIs to MB had not
significantly impacted the UV/visible absorption properties of the chromophore.

Photo-Induced 1O2 and •OH Production by Hybrids
Effective aPDI with hybrids requires that sufficient ROS be produced from the
compounds following illumination. Photo-induced 1O2 and •OH production by hybrids 1-16
was examined by measuring the fluorescence emitted from co-dissolved ROS fluorescent
reporter probes singlet oxygen sensor green (SOSG) and 3’-p-(hydroxyphenyl) fluorescein
(HPF), respectively, following illumination with 652 nm red light. It has been shown that
ROS generation by phenothiazinium PSs does not differ in the presence or absence of cells.37
The 1O2 and •OH data generated were thus relevant to the study’s cell-based experiments
(vide infra). Measurements for MB and hybrids 1-16 were performed in 96-well plates, plots
of fluorescence versus light fluence generated (Supporting Information, Supplementary
Figure 10) and the differences in fluorescence quantum yields relative to MB (%Φ∆) were
calculated (Figure 2).
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Figure 2. Fluorescence quantum yields (Φ∆) from SOSG (1O2) and HPF (•OH) probes
following illumination of compounds 1-16 with 652 nm red light (0-12 J/cm2). Data are
reported as %Φ∆ ± SEM relative to MB from three independent experiments.

Generation of 1O2 and •OH from all hybrids was lower than for MB. For reserpineEPI-MBs 1-4 the levels ranged between 22-55% (of MB), while for Pterostilbene-EPI-MBs
5-8 the levels were less than 21%. INF55-EPI-MBs 9-12 and INF271-EPI-MB 16 showed
greater than ca 2-fold higher 1O2 production than •OH, with1O2 generation by 9 (65%) being
the strongest of all the hybrids. Compound 12 (hereafter referred to as INF55(Ac)en-MB)
generated the second highest 1O2 levels (60%) and was the strongest producer of •OH (30%)
among the INF55-EPI-MB series. Hybrid 16 from the INF271-EPI-MB series exhibited the
third highest levels of 1O2 production (55%).
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In vitro PDI of MRSA USA300
For cell-based in vitro and in vivo experiments it was necessary to identify a non-toxic
vehicle for solubilizing hybrids in aqueous media. Testing the aqueous solubility of
reserpine-EPI-MB 3 (selected after noting its particularly poor aqueous solubility) using
common detergents identified Cremophor EL® (CrEL) as a promising lead (Supporting
Information, Supplementary Figure 11). CrEL was selected for use in all experiments after
confirming it did not change photodynamic 1O2 production by MB (relative to PBS/MeOH,
Supporting Information, Supplementary Figure 10) and because of its reportedly low
toxicity.38
Hybrids 1-16 were screened alongside MB for dose-dependent PDI of MRSA
USA300 over the concentration range of 1-20 µM (652 nm red light, 6 J/cm2). The complete
data set is provided in the Supporting Information, Supplementary Figure 13. A summary of
the activities observed at the highest concentration tested (20 µM) is shown in Figure 3. In
dark control experiments, no significant toxicity was observed for any of the hybrids or MB
and there was no difference between the dark toxicity of MB formulated in CrEL or
PBS/MeOH (Supporting Information, Supplementary Figure 12). A 2 log10 reduction in
survival was observed with MB (20 µM) in PBS upon light application, with an additional 1
log10 of killing seen when MB was formulated in CrEL. INF55(Ac)en-MB 12 showed the
strongest aPDI activity, producing a 3 log10 greater killing effect than MB/CrEL at 20 µM.
INF271-EPI-MBs 13 and 14 also showed higher activity than MB/CrEL, while reserpineEPI-MB 4 and INF55-EPI-MB 10 produced equivalent killing effects (to MB/CrEL). The
remaining hybrids all showed either lower or no activity.
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Figure 3. Photodynamic inactivation of MRSA USA300 by MB and hybrids 1-16 following
illumination with 652 nm red light at 6 J/cm2. All compounds were present at 20 µM. Data
represent the mean of three independent experiments ± SEM.

PDI and uptake studies with S. aureus isogenic NorA efflux mutants
Previous studies with knockout (NorA-, K1758), wild-type (WT, 8325-4) and
overexpressing (NorA++, K2361) S. aureus isogenic NorA efflux mutants showed that NorA
expression correlates with reduced PDI by MB, due to the NorA-mediated efflux reducing
intracellular MB concentrations and associated intracellular ROS.25 Three hybrids exhibiting
both significant ROS production and potent PDI of the MRSA USA300 strain (i.e. 10,
INF55(Ac)en-MB 12 and 14) were selected for studies with the S. aureus NorA efflux
mutants to examine the effects of this pump on hybrid PDI activity.
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PDI of the S. aureus mutants was measured over the concentration range 0-160 µM at
a constant light fluence. In dark control experiments, MB showed some dose-dependent
toxicity at concentrations above 20 µM, especially against the NorA- and NorA++ strains.
The hybrids were generally less toxic than MB at equivalent concentrations (Supporting
Information, Supplementary Figure 14). Upon application of 652 nm red light (10 J/cm2), MB
(20 µM) caused a 2.9 log10 reduction in survival of the NorA- strain, and 2.2 log10 and 1.8
log10 reductions in the WT and NorA++ strains, respectively (Figure 4), in agreement with a
previous report.24
The NorA++ strain showed a pronounced sensitivity to 10 and INF55(Ac)en-MB 12,
exhibiting an 8 log10 reduction in survival at concentrations above 40 µM. The NorA- strain
also showed high sensitivity to INF55(Ac)en-MB 12, while higher concentrations of 10 (80
µM) were required to produce an 8 log10 reduction in this strain. The three strains were
uniformly less sensitive to the INF271-based hybrid 14. The WT strain was the least sensitive
towards all three hybrids at most concentrations.
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Figure 4. PDI of S. aureus NorA efflux mutants by: (a) MB, (b) 10, (c) INF55(Ac)en-MB 12
and (d) 14 following illumination with 652 nm red light at 10 J/cm2. Data represent the mean
± SEM from three independent experiments.

Cellular uptake of 10, INF55(Ac)en-MB 12 and 14 by the three S. aureus NorA
mutants was examined using a fluorescence-based assay. Uptake of MB was highest in the
NorA- strain (3.7 x 109 molecules/cell), reduced in the WT (1 x 109 molecules/cell) and
14

lowest in the NorA++ strain (0.5 x 109 molecules/cell, Figure 5), consistent with
susceptibility to NorA efflux.25 Uptake of the three hybrids was similar and higher than MB
in all strains. Hybrid uptake varied little among the strains despite the differences in NorA
expression, suggesting that unlike MB the compounds are not susceptible to NorA efflux.

Figure 5. Uptake of MB and hybrids 10, INF55(Ac)en-MB 12 and 14 by S. aureus isogenic
NorA efflux mutants. All compounds were present at 20 µM. Data represent the mean ± SEM
from three independent experiments. One-tailed t tests comparing MB uptake into each strain
to uptake of each hybrid showed significant differences (***P < 0.001).

Inhibition of the NorA efflux pump
Having established that 10, INF55(Ac)en-MB 12 and 14 accumulate in S. aureus cells
and that they were not substrates for NorA, experiments were conducted to establish whether
the hybrids also blocked the NorA pump. This was done by comparing PDI of NorA++ S.
aureus cells by MB alone, MB in combination with the NorA EPIs INF55 and INF271 and
MB in the presence of three hybrid surrogates, 30, 31 and 32. The surrogates corresponded to
EPIs INF55 and INF271 functionalized with the (N-Boc-protected)-linker groups present in
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10, 12 and 14, respectively, with no MB attached (See Supporting Information, Section 1 ̶
Chemistry for the structures of 30-32).
NorA++ S. aureus cells were treated with MB (20 µM) both alone and in combination
with the EPIs (10 µM), illuminated with 652 nm red light (0-16 J/cm2) and the survival
fractions determined (Figure 6). For MB alone, a 2 log10 greater kill was observed at the
maximum fluence (16 J/cm2) compared to the dark control. In agreement with previous
findings,25 introduction of INF55 and INF271 potentiated MB PDI activity, affording an
additional 4 log10 killing effect at 16 J/cm2. PDI with MB in the presence of 30-32 was
virtually unchanged from that observed with INF55 and INF271, confirming that the
derivatized EPIs showed equivalent NorA inhibitory effects. Taken together, these results
demonstrate that increased cellular uptake of 10, INF55(Ac)en-MB 12 and 14 (relative to
MB) into S. aureus cells arises from the direct inhibition of the NorA pump (by the appended
EPIs) and not solely because the hybrids evade NorA-mediated efflux.
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Figure 6. PDI of S. aureus NorA++ cells by MB (20 µM) and MB in combination with
INF55, INF271 and derivatized EPIs 30-32 (all 10 µM). Data represent the mean ± SEM
from three independent experiments.

Murine MRSA wound infection aPDI model
INF55(Ac)en-MB 12 was selected as the lead hybrid for in vivo studies where the
goal was to establish whether the superior S. aureus cell uptake and in vitro PDI activity
observed with 12 against MRSA relative to MB translated to increased efficacy in a wholeanimal MRSA infection. Hybrid 12 was assessed alongside MB using the murine needle
back-scratch wound abrasion aPDI model developed by Dai et al.39 This model employs
bioluminescent MRSA Xen3040, 41 for facile infection monitoring and reflects the initial
stages of the wound infection process.39
Immunosuppressed female BALB/c mice were divided into 5 cohorts, each containing
6 animals. Group A served as the negative control (no compound + light), Group B as the
MB dark control (MB + no light) and Group C received MB + light. Group D served as the
dark control for INF55(Ac)en-MB 12 (12 + no light) and Group E received 12 + light. Back17

scratch wounds were introduced onto animals and inoculated with MRSA Xen30. Compound
treatments were added by direct application to infection sites, red light (652 nm) was applied
in 5 doses over 20 min and bioluminescence images were captured after each dose. A
summary of the treatment cohorts and the experimental protocol is provided in the
Supporting Information, Supplementary Figure 15. Representative images from animals in
Groups A-E during the initial ‘light-treatment’ phase of the experiment are provided in the
Supporting Information, Supplementary Figure 16. The quantitative wound bioluminescence
data are presented in Figure 7(a).
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Figure 7. (a) Bioluminescence of MRSA Xen30-infected mouse wounds during initial ‘lighttreatment’ phase. Data represent the mean (± SEM) normalized relative luminescence units
(RLU) emanating from the wounds of 6 mice in each group. (b) Ten day post-treatment
monitoring of infection site bioluminescence. Data represent the mean ± SEM (n = 6) for
each cohort. (c) Photographs of infection sites in Groups A-E at Days 4-6 post-treatment.
In the absence of compound (Group A) the bioluminescence signal decreased less
than 20%, confirming that the bacterial load was stable over the 20 min ‘light-treatment’
period. For the MB dark control (Group B) a 36% reduction in luminescence was observed.
19

Application of light to the MB–treated cohort (Group C) produced a light dose-dependent
PDI response. After 2 min of light application (12 J/cm2) bioluminescence was reduced by
45%, which increased to 70% after 6 min (36 J/cm2) and became undetectable after 20 min
(120 J/cm2). For the INF55(Ac)en-MB 12 dark control (Group D) a 24% reduction in
bioluminescence was seen after 20 min. A remarkable 98% reduction was observed with
INF55(Ac)en-MB 12 after applying light for just 2 min (12 J/cm2) and total loss of the
bioluminescence signal was observed after 6 min.
Post-treatment monitoring of infection sites was performed for 10 days by capturing
daily bioluminescence images (Supporting Information, Supplementary Figure 17). The
bioluminescence signals were quantified and the data are presented in Figure 7(b). A rebound
in the bacterial load, indicated by a ~1.6-fold increase in bioluminescence, was observed in
the control groups (Group A, B and D) after Day 1 and their infections were resolved by Day
10. For the MB + light cohort (Group C), a smaller (1.3-fold) rebound was observed after 1
day and the infections were resolved within 7 days. For the INF55(Ac)en-MB 12 + light
cohort (Group E), no rebound in the bacterial load was observed and the infections were
completely resolved within 4 days. As shown in Figure 7(c), control Groups A, B and D
exhibited minimal signs of healing on Days 4-6. The MB + light cohort (Group C) showed
visible signs healing by Day 6, while animals treated with INF55(Ac)en-MB 12 + light
(Group E) were healed by Day 4.

CONCLUSIONS
The need for continuous development of new therapeutic approaches targeting MRSA
is high since: (i) the evolutionary adaptability of MRSA to antibiotic pressure has proven to
be a remarkably successful survival strategy for this important human pathogen42 and (ii) use
of conventional broad spectrum antibiotics is a risk factor for increasing resistance, especially
20

in healthcare facilities.43 Treatment of MRSA infections with antibiotics, including recently
approved compounds44 and new agents coming through the pipeline,45 will likely afford only
temporary solutions due to the inevitable development of resistance. In contrast, aPDI offers
an attractive and easy-to-apply non-antibiotic alternative for treating localized MRSA
infections that limits the development of resistance because of its multi-target/non-specific
mode of action. aPDI approaches are predicted to have much longer effective clinical
lifetimes than antibiotics.46 In an era where there is an urgent need to identify anti-infective
solutions beyond traditional antibiotics, aPDI offers extraordinary promise. Despite this, there
have been surprisingly few clinical studies exploring aPDI46-53.
This study explored the hypothesis that hybrid molecules, consisting of a NorA EPI
covalently tethered to MB via a non-cleavable linker, could show increased aPDI activity
relative to MB against MRSA. The hypothesis was founded on the idea that attaching the
NorA EPI would increase intracellular concentrations of MB and associated intracellular
ROS, leading to enhanced phototoxic effects. We predict that clinical use of such
photoantimicrobials could provide effective aPDI treatments at low compound/light doses,
thus reducing potential for ROS-mediated damage to host tissues. This is because
concentrating ROS inside bacteria would place a protective (cell membrane) barrier between
the phototoxic species and host cells. Preserving host tissues around infection sites should
also provide benefits for wound healing through photobiomodulation effects.54, 55
UV/Visible absorption spectra of the 16 hybrids showed that the wavelengths and
extinction coefficients of bands arising from the MB chromophore remained largely
unchanged (relative to MB), indicating that the absorption properties of MB were not affected
by the appended structures. INF55-EPI-MBs 10 and 12 and INF271 EPI-MBs 14 and 16
showed the strongest PDI of MRSA and uptake of 10, 12 and 14 by the S. aureus NorA panel
was much greater than MB and varied little across the phenotypes. Together these findings
21

indicated that EPI-MBs are not substrates for the NorA efflux pump. PDI experiments with
MB in combination with INF55, INF271 and INF55- and INF271-containing compounds that
lacked an appended MB group confirmed that these three hybrids also block the NorA pump.
The lead hybrid INF55(Ac)en-MB 12 was advanced to in vivo studies to establish
whether its superior in vitro effects relative to MB translated to a vertebrate animal MRSA
aPDI infection model. During the light treatment phase of the experiment INF55(Ac)en-MB
12 produced a more potent and rapid light-dose response than MB, while during the posttreatment monitoring period the bacterial re-growth observed with MB was not seen with 12.
More rapid clearance of bacteria was also observed and, crucially, wound healing occurred
much earlier following treatment with INF55(Ac)en-MB 12 than MB.
This study demonstrates that attaching an EPI to a photosensitizer can increase aPDI
efficacy, both in vitro and in vivo. The findings pave the way for pre-clinical assessment of
aPDI with INF55(Ac)en-MB 12 in topical MRSA infections and support wider exploration of
the EPI-PS approach as a method for treating drug resistant localized infections. As our
fundamental understanding of microbial efflux pumps matures and our arsenal of EPI
scaffolds expands, especially against Gram-negative pathogens, numerous opportunities will
likely emerge for creating effective new EPI-PS hybrid photoantimicrobials.

METHODS
Chemistry. Complete details of the syntheses of hybrids 1-16 and all synthetic intermediates
are provided in the Supporting Information, Section 1 ̶ Chemistry.

UV/Visible Spectroscopy. UV/Visible spectra were recorded over the wavelength range 250750 nM using 10 µM solutions of MB and 1-16 in MeOH at 23 oC using a Shimadzu UV1700 PharmaSpec Spectrophotometer spectrometer.
22

1

O2 and •OH Experiments. Solutions of MB and hybrids 1-16 (50 µM, 85 µL) in phosphate-

buffered saline (PBS, pH 11) were added to 96-well plates (Fisher Scientific, USA), followed
by 40 µL of SOSG (5 µM) or HPF (5 µM) probes in PBS. D2O (40 µL) was added to each
well to increase the life-time of •OH and 1O256, 57 and MeOH (40 µL) was added as cosolvent. Plates were illuminated with red light (652 nm) for times corresponding to 0-12
J/cm2 fluence and plots of fluorescence versus fluence produced (Supporting Information,
Supplementary Figure 10). A schematic summary of the experiments is provided in the
Supporting information, Supplementary Figure 9.
A noncoherent light source (LC122; LumaCare, London, UK) with 30 nm-band-pass
filters at ranges of 652 ± 15 nm was used for illumination. The total power output from the
fibre bundle was 300 mW. Plates were arranged to give irradiance of 100 mW/cm2. The
power (P) in watts was equal to the energy (E) in joules, divided by the illumination time (t)
in seconds:
P(W) = E(J) / t(s)
So
Watt/cm2 = joule/cm2 per second
A 30 sec illumination at irradiance 100 mW/cm2 over a 3 cm2 area provides a fluence of
1000 mJ/cm2, or 1 J/cm2. Fluence was proportionally increased by extending the period of
illumination. A microplate spectrophotometer was used in “slow kinetic” mode for detecting
fluorescence. For SOSG, emission was measured at 505 nm following excitation at 525 nm (2
nm monochromator band pass). For HPF, fluorescence emission was measured at 525 nm
after excitation at 492 nm (2 nm monochromator band pass).
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Fluorescence quantum yield is defined as the ratio of the number of photons emitted
from a fluorophore to the number of photons absorbed. Relative fluorescence quantum yields
in the SOG and HPF experiments were determined by comparing the observed fluorescence
for hybrids 1-16 to MB, which produces known quantum yields under the experimental
conditions (Φ∆ SOG = 0.52, Φ∆ HPF = 0.46). Quantum yields for the hybrids in each assay
relative to MB were calculated using the equation:
Int
Φ∆ = Φ∆MB X

2

-A

1-10
X

IntMB

n

MB

X
-A

1-10

2

nMB

Where Int is the area under the emission curve (on a wavelength scale), A is optical density at
the excitation wavelength and n is the refractive index of the solvent. The subscript MB refers
to the respective values for methylene blue. Since the same energies of light and the same
solvents were used for MB and hybrids, the relative quantum yields could be obtained by
measuring the area under the fluorescence curves (Supporting Information, Supplementary
Figure 10) and dividing by the area under the MB curve. For each fluorescence curve, a bestfit trend line was obtained using polynomial regression and the relative integration calculated
over the fluence range 0-10 J/cm2 for SOG and 0-12 J/cm2 for HPF. Further details regarding
these experiments can be found in the Supporting Information, Section 3 − 1O2 and •OH
experiments.

Bacterial strains and culture conditions. Community Associated (CA)-MRSA (strain
USA300, human isolate/Clinical Microbiology, Massachusetts General Hospital, MA, USA)
was used for in vitro PDI screening of hybrids 1-16. Mouse adapted S. aureus wild-type
strain 8325-4 (Hamblin Lab), isogenic NorA efflux knockout strain (NorA-, SA-1758,
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Hamblin Lab) and NorA overexpressing strain (NorA++, SA-K2378, Hamblin Lab)58-60 were
used for PDI and uptake studies with 10, INF55(Ac)en-MB 12 and 14. The bioluminescent
MRSA Xen30 (LuxABCDE operon) strain used in the animal infection model was obtained
from the Dai Lab, Wellman Center for Photomedicine, Massachusetts General Hospital, MA,
USA.40 Bacterial cells were cultured in Mueller–Hinton Broth (MHB) and growth was
monitored using a Shimadzu Mini 1240 spectrometer at 600 nm (OD600).

In vitro PDI studies with S. aureus MRSA USA300 and NorA efflux mutants. MRSA
USA300 cells (108 cfu/mL) were incubated with hybrids 1-16 or MB (0-20 µM) for 30 min at
room temperature in 96-well plates before being illuminated with 652 nm light (6 J/cm2).
Wells were stirred constantly during illumination to ensure bacteria did not settle and were
adequately mixed for sampling. Aliquots were removed, 10-fold serially diluted in PBS to
provide 10−1 to 10−6 dilutions, streaked horizontally across square brain heart infusion agar
plates and incubated overnight at 37 °C. Colony forming units were counted and survival
fractions determined, as described by Jett et al.61 Data are reported as log10 (reduction in
survival fraction). Identical procedures were employed for PDI studies with 10,
INF55(Ac)en-MB 12 and 14 against the NorA isogenic mutants, except for use of 10 J/cm2
fluence. For dark controls, the same procedures were used without the illumination step.

Cell uptake studies with S. aureus NorA efflux mutants. Uptake experiments were based on
the procedure reported by Tegos et al.25 Briefly, bacterial suspensions (108 cfu/mL) were
incubated with compound (20 µM) in the dark at room temperature for 30 min. The cell
suspensions were centrifuged (9,000 × g, 1 min) and the supernatant aspirated. The bacterial
pellet was washed twice with sterile PBS (1 mL), centrifuged (9,000 × g, 1 min) and the
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supernatant aspirated. The pellet was digested in 3 mL of 0.1 M NaOH containing 1%
sodium dodecyl sulfate (SDS) for 48 h to give a homogenous solution. Fluorescence of the
solution was measured using a spectrofluorimeter (FluoroMax3; SPEX Industries, Edison,
NJ) with excitation at 650 nm and emission over the range 655-720 nm. Fluorescence
calibration curves were generated from serial dilutions of each compound in 0.1 M NaOH/1%
SDS. If necessary, cell digest solutions were diluted with 0.1 M NaOH/1% SDS until
fluorescence fell within the linear region of the calibration curve. Cellular uptake was
calculated by dividing the amount of compound (nmol) in the dissolved pellet by the number
of cfu obtained from serial dilutions and converting to molecules/cell using Avogadro's
number.

NorA efflux pump inhibition studies. Compounds 30 and 31, corresponding to the (Bocprotected) INF55-linker groups found in 10 and 12, respectively, and 32, corresponding to the
(Boc-protected) INF271-linker region in 14, were intermediates in the synthesis of the parent
hybrids (Supporting Information, Section 1 ̶ Chemistry). NorA++ S. aureus cells were
incubated for 30 min at room temperature with INF55, INF271, 10, 12 or 14 (all 10 µM) and
MB (20 µM) in 96-well plates before illumination with increasing fluences of 652 nm red
light (0-16 J/cm2). Aliquots were removed and the survival fractions determined, as described
above for the in vitro PDI studies.

Murine MRSA wound infection model. All procedures were approved by the Subcommittee
on Research Animal Care at the Massachusetts General Hospital (MA, USA) and were in
accordance with the guidelines of the National Institutes of Health (NIH). Stocks of MB and
INF55(Ac)en-MB 12 were freshly prepared as CrEL/PBS micellar solutions to final
concentrations of 200 µM (Supporting Information, Section 4(b) Preparation of CrEL
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micellar solutions). Bioluminescent MRSA Xen3040 cultures were grown overnight in brain
heart infusion (BHI) media at 37 °C with 100 rpm orbital shaking. Bacterial growth was
assessed using an Evolution 300 UV/Vis Spectrophotometer (Thermo Scientific, Waltham,
MA, USA). Cultures of 0.8 optical density at 600 nm (OD600) corresponded to 108 cfu/mL.
Cells were washed with PBS, re-suspended in PBS to a density of 108 cfu/mL and used for
wound inoculations.
Adult 7-8 week old female BALB/c mice weighing 17-21 g (Charles River
Laboratories, Wilmington, MA, USA) were housed one per cage with access to food and
water ad libitum while being maintained on a 12-hour light-dark cycle at 21 °C (relative
humidity range 30-70%). Mice were immunosuppressed with intraperitoneal (i.p.)
cyclophosphamide injections62 4 days (150 mg/kg i.p.) and 1 day (100 mg/kg i.p.) prior to
MRSA Xen30 inoculation. On the day of inoculation, mice were anesthetized with i.p.
injections of ketamine (100 mg/kg)/xylazine (10mg/kg) cocktail and their dorsal surfaces
shaved. Skin abrasion wounds were introduced onto the dorsal surfaces by using a 28-gauge
needle (Micro-Fine IV, Becton Dickinson, Franklin Lakes, NJ) to scratch 6 x 6 cross-hatch
lines in a square covering 1.0 cm2. The scratches were applied such that only the stratum
corneum and upper-layer of the epidermis were damaged. Five minutes after wounding a 40
µL aliquot was drawn from the 108 cfu/mL suspension of MRSA Xen 30 in PBS and spread
evenly over the wound area using a micropipette. Bioluminescence images were captured
immediately after inoculation. Thirty minutes after inoculation, MB and INF55(Ac)en-MB 12
(40 µL of 200 µM stock solutions) were introduced to infection sites on animals from Groups
B-E using a micropipette and a second bioluminescence image was captured. Fifteen minutes
after compound addition (to allow binding/penetration into cells) a third image was captured
(Time = 0). Mice were then illuminated with 652 nm light in 2, 4, 8, 4 and 2 min aliquots
over a 20 min period, corresponding to fluences of 12, 36, 84, 108 and 120 J/cm2.
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Bioluminescence images were captured after each light dose. For the negative control Group
A and dark controls Groups B and D, images were captured at the equivalent times postinoculation. Bioluminescence images were captured daily for 10 days following treatment to
monitor clearance of the infection and daily photographs were taken (Nikon Coolpix L20
camera) to record wound healing.
A noncoherent light source (LC122; LumaCare, London, UK) with interchangeable
fibre bundles and 30 nm band-pass filters (652 ± 15 nm) was used for light application.
Power output from the fibre bundle was 300 mW, with spots positioned at the required
distance from animals to give an irradiance of 100 mW over the 1.0 cm2 wound area.
Bioluminescence images were captured using a Hamamatsu Photonics KK (Bridgewater, NJ)
imaging system,39 consisting of an intensified charge-coupled-device (ICCD), camera
(C2400-30H; Hamamatsu), camera controller, imaging box, image processor (C5510-50;
Hamamatsu) and color monitor (PVM 1454Q; Hamamatsu). Mice were placed on an
adjustable stage in the specimen chamber and infected areas positioned directly under the
camera. Light-emitting diodes were mounted inside the imaging box to supply light for
dimensional imaging. The setup allowed a grayscale background image of each mouse to be
taken. Luminescence emanating from wounds was captured using an integration time of 2
min at the maximum setting on the image-intensifier control module. ARGUS software
(Hamamatsu) was used to present luminescence as false-colour images (pink most intense,
blue least intense) superimposed on the grayscale background and to calculate relative
luminescence units (RLU) from total pixel values.
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